Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

See All Experts

featured

Published in Oncology

Journal Scan / Research · February 15, 2024

Treatment-Free Remission After a Second TKI Discontinuation Attempt in Patients With CML Retreated With Dasatinib

Leukemia

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Leukemia

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial

Leukemia 2024 Jan 26;[EPub Ahead of Print], H Flygt, S Söderlund, J Richter, S Saussele, P Koskenvesa, L Stenke, S Mustjoki, A Dimitrijevic, J Stentoft, W Majeed, L Roy, D Wolf, A Dreimane, BT Gjertsen, T Gedde-Dahl, E Ahlstrand, B Markevärn, H Hjorth-Hansen, J Janssen, U Olsson-Strömberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Treatment-Free Remission After a Second TKI Discontinuation Attempt in Patients With CML Retreated With Dasatinib

Additional Info

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial

Further Reading

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Recently Updated